SCHEMBL4319103

SCHEMBL4319103

CC(C)(C)OC(=O)N1CCN(c2cccc3c2ccn3[Si](C)(C)C(C)(C)C)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
SMARCA2 P51531 1/20 0.42
SMARCA4 P51532 1/20 0.42
PBRM1 Q86U86 1/20 0.42
ACHE P22303 2/20 0.42
CKS1B P61024 1/20 0.42
SKP1 P63208 1/20 0.42
SKP2 Q13309 1/20 0.42
HTR6 P50406 1/20 0.42
NAMPT P43490 1/20 0.41
GPR119 Q8TDV5 1/20 0.41
BACE1 P56817 3/20 0.40
KIT P10721 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5704933 0.86 CHRM2 (0.43) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL4867452 0.82 CHRM2 (0.48) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL4863963 0.82 CHRM2 (0.48) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL6422224 0.81 CHRM2 (0.47) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL5751919 0.81 HTR6 (0.47) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL6195500 0.81 HTR6 (0.49) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL6195963 0.80 CHRM2 (0.48) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL5704804 0.79 CKS1B (0.47) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL7531503 0.77 CHRM2 (0.46) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL20135184 0.76 SCN9A (0.47) CHRM2CHRM4CHRM1CHRM3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7524839-B2 Compounds, their use and preparation BIOVITRUM AM (PUBL.) 2009-04-28 US disclosed
CN-101298433-A 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy BIOVITRUM AB (SE) 2008-11-05 CN disclosed
CN-100378074-C 2-, 3-, 4-or 5-substituted N1- (phenylsulfonyl) indoles and their therapeutic use BIOVITRUM AB (SE) 2008-04-02 CN disclosed
US-7087750-B2 Compounds, their use and preparation BIOVITRUM AB (SE) 2006-08-08 US disclosed
CN-1714077-A 2-, 3-, 4-or 5-substituted N1- (phenylsulfonyl) indoles and their therapeutic use BIOVITRUM AB (SE) 2005-12-28 CN disclosed
US-20050256106-A1 Novel compounds, their use and preparation BIOVITRUM AB, A STOCKHOLM, SWEDEN CORPORATION 2005-11-17 US disclosed
US-20020165251-A1 Novel compounds, their use and preparation PROXIMAGEN NEUROSCIENCE PLC (GB) 2002-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165251-A1 Novel compounds, their use and preparation HTR6, HTR1A, HTR5A CHRM2 198/4885CHRM4 244/4885CHRM1 187/4885
US-20050256106-A1 Novel compounds, their use and preparation HTR6, HTR3C, HTR1A CHRM2 111/4885CHRM4 196/4885CHRM1 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.